Custom Development & Manufacturing Business(CDMO)(For Regenerative Medicine Developers)

Aspect Smaller scale of clinical trials than in Europe and US

The approval of the Japanese Ministry of Health, Labour and Welfare (MHLW) is necessary in order to market regenerative medical products in Japan. Clinical trials to confirm the efficacy and safety of the products must be conducted in order to obtain marketing approval, but the scale of clinical trials that is required by the Japanese regulatory authorities is not as large as that required for pharmaceutical development in Europe and the United States, and the special characteristics of regenerative medicine are taken into consideration when determining the necessary number of cases. Once the data obtained in the clinical trials is submitted to and approved by the MHLW, it is possible to proceed with practical application.
A system of accelerated approval (conditional and time-limited approval) was introduced by the PMD Act, which came into effect on November 25, 2014. This system, designed to reflect the nonuniform nature of regenerative products as a class, makes it possible to obtain conditional and time-limited marketing approval if safety is confirmed and there is presumptive evidence of efficacy (from Article 23-26 of the PMD Act).
This ground-breaking system exists only in Japan, and it is one of the elements that make speedy productization possible.

Aspect In product manufacture and quality control, a level of meticulousness found only in Japan

Thus far, J-TEC has placed 5 regenerative medical products on the market: Autologous Cultured Epidermis, Autologous Cultured Cartilage, Autologous Cultured Corneal Epithelium, Autologous Cultured Oral Mucosal Epithelium, and Autologous Cultured Epidermis Maintaining Melanocytes.

We are now providing a stable supply of these products, and they are being used throughout Japan. In addition to the experience and knowledge gained through developing these products, J-TEC possesses every type of organization necessary in order to develop and market regenerative medical products, from R&D through clinical development, regulatory affairs, production, quality assurance, and sales. Thanks to this, we have achieved consistent and efficient operations. Moreover, we have built relationships of trust through the development of our own products and collaboration with the Japanese regulatory authorities. We think that the knowledge and knowhow we possess will be useful to our customers.
J-TEC supports customers through product manufacture and quality control with a level of meticulousness found only in Japan.

Achievements of J-TEC's custom development and manufacturing business(CDMO & CRO)

We provide comprehensive and seamless support from the development stage to practical application, regardless of the type of cells (somatic cells, stem cells, iPS cells) or product form.

Because each contract includes multiple types of support, the total number of cases is different from the number of orders on a contract basis.

J-TEC manufactures products with guaranteed safety under the motto of making regenerative medicine a standard healthcare.

Aspect Cooperative Japanese doctors

The understanding and cooperation of the doctors who actually use commercialized regenerative medical products is indispensable to the spread of regenerative medicine. Japan has many extremely cooperative doctors, and a virtuous cycle exists whereby the doctors search for optimal methods of using the products in their practices and then provide feedback to the company that developed them, leading to further product improvements. By commercializing your product in Japan first, you can create better products in collaboration with these doctors. Why not bring out your product in Japan first and then use that as a foothold for deploying it to the rest of the world?